BofA initiates Supernus Pharmaceuticals stock at buy on merger scale

BofA’s initiation of Supernus Pharmaceuticals stock at a buy rating, tied to merger scale considerations, signals potential value creation through consolidation in the healthcare sector. For middle-market credit professionals, this highlights the strategic importance of merger-driven growth and its impact on credit profiles. Understanding how such deals can influence leverage, cash flow stability, and refinancing opportunities is crucial for assessing risk and opportunity in leveraged finance portfolios exposed to the pharmaceutical space.